Sertraline and nortriptyline: Heart rate, cognitive improvement and quality of life in depressed elderly

McEntee, William J.; Ko, Geumbo; Richter, E.M.

doi:10.1016/0924-977x(96)87466-9

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be mentioned, however, that comparison of the studies is very restricted as Sabbe et al [9] administered the copying tasks only twice during the 6-week treatment period, whereas we assessed performance at six different moments in order to rule out the impact of any practice effect. It is also worth noting that the present results correspond with previous research that directly compared sertraline with fluoxetine [26] and nortriptyline [27] for the treatment of depressed elderly patients: whereas all agents demonstrated a comparable clinical efficacy, sertraline was reported to induce a greater cognitive and psychomotor improvement compared with fluoxetine and nortriptyline. Furthermore, a double-blind comparison of the two agents in a 24-week regimen already indicated sertraline to have a better effect on psychomotor symptoms than fluoxetine, although the comparison was based on the retardation item of the HDRS only [28] .…”

Section: Discussionsupporting

confidence: 79%

Psychomotor Changes in Major Depressive Disorder during Sertraline Treatment

Schrijvers

Maas

Pier³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

Background: There is a relative scarcity of studies on major depressive disorder that use objective assessment methods to explore the psychomotor effects of antidepressants. Striatal dopaminergic disturbances are known to be involved in the pathogenesis of major depressive disorder that is associated with psychomotor retardation. Because of its additional dopaminergic mechanism, the psychomotor effects of the selective serotonin reuptake inhibitor sertraline merit further exploration. Methods: In 19 patients diagnosed with a current major depressive episode, clinical variables and graphic motor activity were assessed applying digitized figure copying tasks during a 6-week regimen of sertraline. Patients’ baseline and weekly psychomotor performance was compared with the outcomes of 22 healthy, unmedicated controls. Results: Patients’ psychomotor slowing had improved after 6 weeks on sertraline as reflected by reductions in initiation and movement times on the simple line and figure copying tasks and decreased initiation times for the complex figure copying task relative to their baseline outcomes. Conclusions: The current study found evidence pointing to potential beneficial effects of sertraline after a 6-week treatment period in the lower-order cognitive and motor components involved in the graphic motor performance of depressed patients. The present findings are discussed in terms of the mechanism of action of sertraline.

show abstract

Section: Discussionsupporting

confidence: 79%

Psychomotor Changes in Major Depressive Disorder during Sertraline Treatment

Schrijvers

Maas

Pier³

et al. 2009

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…and was statistically significant at week 6. Similar robust and statistically significant improvements in the performance of the DSST by sertraline relative to nortriptyline were seen in a similarly designed 12-week study in 210 elderly patients (McEntee et al, 1996). In addition, sertraline-treated patients showed significantly greater improvements on the Shopping List Task (Fig.…”

Section: Cognitive Dysfunctionmentioning

confidence: 54%

“…Sertraline treatment does not appear to be associated with cognitive or psychomotor impairment, and produces an improvement in these functions in elderly depressed patients (McEntee et al, 1996), and to a significantly greater degree than that seen with fluoxetine (Newhouse et al, 1996). The lack of effect of fluoxetine and other SSRIs on dopaminergic neurotransmission may account for their apparently poor efficacy in patients with melancholia.…”

Section: Melancholiamentioning

confidence: 96%

“…Remission rates were 56% for sertraline and 43% for moclobemide (p=0.04). In addition, sertraline (50-150 mg/day) was significantly more effective than nortriptyline (25-100 mg/day) in ameliorating the anxiety/hostility factor of the patient-rated Profile of Mood States in a 12-week study in depressed elderly patients (McEntee et al, 1996).…”

Section: Anxietymentioning

confidence: 99%

“…Thus, the greater improvements seen m sertraline relative to fluoxetine-treated patients on neurophysiolgical assessments may be in line with findings from other comparative studies between these two agents suggesting differential efficacy in patients with vegetative symptoms such Figure 12 Mean changes at last visit m Digit Symbol Substitution Test and Shopping List Task score m 12-week study m 210 elderly depressed patients treated with sertraline-or nortriptyline. Adapted from McEntee et al (1996) as sleep, weight and psychomotor disturbance and general somatic symptoms. These differences may be related to the additional dopaminergic activity of sertraline.…”

Section: Cognitive Dysfunctionmentioning

confidence: 99%

See 2 more Smart Citations

Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life

Goodnick¹,

Goldstein

1998

J Psychopharmacol

View full text Add to dashboard Cite

Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

show abstract